NCT04977232

Brief Summary

This is a pilot study using game intervention as an adjuvant treatment, to evaluate the effect of the video game on anhedonia and associated functional change of brain in patients with depression. Participants will be randomized to Experimental group receiving a 8-week treatment of antidepressant drugs and game intervention, or Control group receiving a 8-week treatment of antidepressant drugs. Magnetic resonance imaging scanning and assessment of clinical characteristics and cognitive function were conducted before and after the intervention.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
50

participants targeted

Target at P25-P50 for not_applicable depression

Timeline
Completed

Started Sep 2021

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

July 13, 2021

Completed
13 days until next milestone

First Posted

Study publicly available on registry

July 26, 2021

Completed
2 months until next milestone

Study Start

First participant enrolled

September 9, 2021

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 31, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 31, 2022

Completed
Last Updated

August 21, 2024

Status Verified

August 1, 2024

Enrollment Period

1.3 years

First QC Date

July 13, 2021

Last Update Submit

August 20, 2024

Conditions

Outcome Measures

Primary Outcomes (3)

  • Snaith-Hamilton-Pleasure Scale (SHAPES)

    Pre-post assessment of anhedonia via the Snaith-Hamilton-Pleasure Scale (SHAPES). Raw score range is 14-56. A higher score indicates a worse outcome.

    From baseline to 8 weeks

  • Temporal Experience of Pleasure Scale (TEPS)

    Pre-post assessment of anhedonia via the Temporal Experience of Pleasure Scale (TEPS). Raw score range is 20-120. A lower score indicates a worse outcome.

    From baseline to 8 weeks

  • Hamilton Depression Rating scale (HAMD)

    Pre-post assessment of depressive symptoms via Hamilton Depression Rating scale (HAMD). Raw score range is 0-52. Higher scores indicate more severe depression.

    From baseline to 8 weeks

Secondary Outcomes (5)

  • Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)

    From baseline to 8 weeks

  • The Stroop test

    From baseline to 8 weeks

  • Wisconsin Card Sorting Test (WCST)

    From baseline to 8 weeks

  • Rumination Responses Scale

    From baseline to 8 weeks

  • Magnetic Resonance Imaging data

    From baseline to 8 weeks

Study Arms (2)

Escitalopram + game intervention

EXPERIMENTAL

Escitalopram treatment and game intervention are given in combinations for 8 weeks.

Drug: EscitalopramBehavioral: Game intervention

Escitalopram

ACTIVE COMPARATOR

Escitalopram treatment for 8 weeks

Drug: Escitalopram

Interventions

Selective serotonin reuptake inhibitors (SSRI) were most commonly used first line pharmacotherapy for depression.

Also known as: Lexapro
EscitalopramEscitalopram + game intervention

Participants will be instructed to play the commercial video game for about 30-60 minutes at least three times per week.

Escitalopram + game intervention

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • a diagnosis of Major Depressive Disorder according to DSM IV or V and validated via Mini International Neuropsychiatric Interview (M.I.N.I.)
  • right handedness
  • capability of understanding and finishing self-rating scales
  • capability of providing informed consent

You may not qualify if:

  • any other major psychiatric disorders following DSM-5 diagnostic criteria
  • neurological diseases
  • a history of drug abuse
  • suicidal risk
  • pregnancy
  • any contraindication for brain MRI scan.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

The Second Xiangya Hospital of Central South University

Changsha, China

Location

MeSH Terms

Conditions

Depression

Interventions

Escitalopram

Condition Hierarchy (Ancestors)

Behavioral SymptomsBehavior

Intervention Hierarchy (Ancestors)

PropylaminesAminesOrganic ChemicalsNitrilesBenzofuransHeterocyclic Compounds, 2-RingHeterocyclic Compounds, Fused-RingHeterocyclic Compounds

Study Officials

  • Wenbin Guo

    Central South University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Professor of Psychiatry Department of Psychiatry of the Second Xiangya Hospital, Central South University

Study Record Dates

First Submitted

July 13, 2021

First Posted

July 26, 2021

Study Start

September 9, 2021

Primary Completion

December 31, 2022

Study Completion

December 31, 2022

Last Updated

August 21, 2024

Record last verified: 2024-08

Locations